Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures

por Larbouret, Christel, Gros, Laurent, Pèlegrin, André, Chardès, Thierry
Publicado 2021

Nitrogen Exchanges: Testing the Hypothesis of a Country without Agricultural Production

por Slak, M.-F., Commagnac, L., Pointereau, P., Larbouret, S., Lucas, C., Muller, S.
Publicado 2001

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficki...

por Lanotte, Romain, Garambois, Véronique, Gaborit, Nadège, Larbouret, Christel, Musnier, Astrid, Martineau, Pierre, Pèlegrin, André, Chardès, Thierry
Publicado 2020

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

por Le Clorennec, Christophe, Lazrek, Yassamine, Dubreuil, Olivier, Larbouret, Christel, Poul, Marie-Alix, Mondon, Philippe, Melino, Gerry, Pèlegrin, André, Chardès, Thierry
Publicado 2016

Letrozole sensitizes breast cancer cells to ionizing radiation

por Azria, David, Larbouret, Christel, Cunat, Severine, Ozsahin, Mahmut, Gourgou, Sophie, Martineau, Pierre, Evans, Dean B, Romieu, Gilles, Pujol, Pascal, Pèlegrin, Andre
Publicado 2005

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer

por Azria, D, Larbouret, C, Garambois, V, Kramar, A, Martineau, P, Robert, B, Aillères, N, Ychou, M, Dubois, J B, Pèlegrin, A
Publicado 2003

ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells

por Le Clorennec, Christophe, Lazrek, Yassamine, Dubreuil, Olivier, Sampaio, Carla, Larbouret, Christel, Lanotte, Romain, Poul, Marie-Alix, Barret, Jean-Marc, Prost, Jean-François, Pèlegrin, André, Chardès, Thierry
Publicado 2019

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

por Tosi, Diego, Pérez-Gracia, Esther, Atis, Salima, Vié, Nadia, Combès, Eve, Gabanou, Mélissa, Larbouret, Christel, Jarlier, Marta, Mollevi, Caroline, Torro, Adeline, Del Rio, Maguy, Martineau, Pierre, Gongora, Céline
Publicado 2018

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer

por Ho-Pun-Cheung, Alexandre, Bazin, Hervé, Gaborit, Nadège, Larbouret, Christel, Garnero, Patrick, Assenat, Eric, Castan, Florence, Bascoul-Mollevi, Caroline, Ramos, Jeanne, Ychou, Marc, Pèlegrin, André, Mathis, Gérard, Lopez-Crapez, Evelyne
Publicado 2012

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial...

por Assenat, Eric, Azria, David, Mollevi, Caroline, Guimbaud, Rosine, Tubiana-Mathieu, Nicole, Smith, Denis, Delord, Jean-Pierre, Samalin, Emmanuelle, Portales, Fabienne, Larbouret, Christel, Robert, Bruno, Bibeau, Frédéric, Bleuse, Jean-Pierre, Crapez, Evelyne, Ychou, Marc, Pèlegrin, André
Publicado 2015

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models

por Rabia, Emilia, Garambois, Véronique, Hubert, Julie, Bruciamacchie, Marine, Pirot, Nelly, Delpech, Hélène, Broyon, Morgane, Theillet, Charles, Colombo, Pierre-Emmanuel, Vie, Nadia, Tosi, Diego, Gongora, Celine, Khellaf, Lakhdar, Jarlier, Marta, Radosevic-Robin, Nina, Chardès, Thierry, Pèlegrin, André, Larbouret, Christel
Publicado 2021

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

por Marzi, L, Combes, E, Vié, N, Ayrolles-Torro, A, Tosi, D, Desigaud, D, Perez-Gracia, E, Larbouret, C, Montagut, C, Iglesias, M, Jarlier, M, Denis, V, Linares, L K, Lam, E W-F, Martineau, P, Del Rio, M, Gongora, C
Publicado 2016

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

por Rabia, Emilia, Garambois, Véronique, Dhommée, Christine, Larbouret, Christel, Lajoie, Laurie, Buscail, Yoan, Jimenez-Dominguez, Gabriel, Choblet-Thery, Sylvie, Liaudet-Coopman, Emmanuelle, Cerutti, Martine, Jarlier, Marta, Ravel, Patrice, Gros, Laurent, Pirot, Nelly, Thibault, Gilles, Zhukovsky, Eugene A., Gérard, Pierre-Emmanuel, Pèlegrin, André, Colinge, Jacques, Chardès, Thierry
Publicado 2023

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

por Thomas, GaëLle, ChardèS, Thierry, Gaborit, NadèGe, Mollevi, Caroline, Leconet, Wilhem, Robert, Bruno, Radosevic-Robin, Nina, Penault-Llorca, FréDéRique, Gongora, CéLine, Colombo, Pierre-Emmanuel, Lazrek, Yassamine, Bras-Goncalves, Rui, Savina, Ariel, Azria, David, Bazin, Hervé, PèLegrin, André, Larbouret, Christel
Publicado 2014